Nectar Lifescience's Q1 FY 2025-26 Quarterly Results

Result Summary

• Nectar Lifescience Ltd reported a 36.5% quarter-on-quarter (QoQ) decrease in its consolidated revenues for the quarter-ended Jun (Q1 FY 2025-26). On a year-on-year (YoY) basis, it witnessed a decline of 21.9%.
• Its expenses for the quarter were down by 12.5% QoQ and up 6.4% YoY.
• The net profit decreased 10816.9% QoQ and decreased 2229.0% YoY.
• The earnings per share (EPS) of Nectar Lifescience Ltd declined at 2.82 during Q1 FY 2025-26.

Financial Statments for Q1 FY 2025-26

---

Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results

Company Overview

Nectar Lifescience Ltd is a company primarily engaged in the pharmaceutical industry. The company is known for manufacturing and supplying a range of active pharmaceutical ingredients (APIs), finished formulations, and phytochemicals. The pharmaceutical sector is a rapidly evolving field with continuous advancements and innovations. Nectar Lifescience Ltd has been involved in the development and commercialization of high-quality products catering to different therapeutic areas. At present, there are no specific recent developments or major announcements available that pertain to Nectar Lifescience Ltd within the scope of this report. The company operates in a highly competitive market, where regulatory compliance and adherence to quality standards are of utmost importance.

Revenue

In Q1FY26, Nectar Lifescience Ltd reported a total income of ₹281.02 crores, which marks a substantial decrease when compared to the previous quarter (Q4FY25), where the total income was ₹442.84 crores, reflecting a decline of 36.5%. Additionally, when compared to the same quarter in the previous fiscal year (Q1FY25), where the total income was ₹359.85 crores, there is a year-over-year decrease of 21.9%. This downward trend in total income indicates a significant reduction in revenue generation over both the quarterly and yearly periods under review.

Profitability

The profitability metrics for Nectar Lifescience Ltd in Q1FY26 have shown a marked downturn compared to both the preceding quarter and the same quarter of the previous year. The company reported a loss before tax of ₹96.75 crores, a stark contrast to the profit before tax of ₹11.11 crores in Q4FY25, and ₹4.92 crores in Q1FY25. This represents a quarter-over-quarter decline of 970.8% and a year-over-year decline of 2066.5%. The tax expense also shows a negative value of ₹33.52 crores in Q1FY26, compared to a positive tax expense of ₹10.52 crores in Q4FY25 and ₹1.95 crores in Q1FY25. The profit after tax has decreased to a negative ₹63.23 crores in Q1FY26 from ₹0.59 crores in Q4FY25 and ₹2.97 crores in Q1FY25, marking a quarter-over-quarter change of -10816.9% and a year-over-year change of -2229.0%. The earnings per share (EPS) in Q1FY26 is at -₹2.82, a steep decline from ₹0.03 in Q4FY25 and ₹0.13 in Q1FY25.

Operating Metrics

The operating metrics of Nectar Lifescience Ltd for Q1FY26 reflect a challenging quarter. Total expenses amounted to ₹377.78 crores, showing a decrease from the previous quarter's ₹431.73 crores, a drop of 12.5%. However, when compared to Q1FY25, where total expenses were ₹354.94 crores, there is a year-over-year increase of 6.4%. This indicates a reduction in operating costs quarter-over-quarter, yet an overall increase compared to the previous year. These figures are crucial in assessing the company's cost management and operational efficiency over time. The significant changes in financial metrics suggest variations in operational activities, which could be attributed to various internal or external factors affecting the company's performance during this period.